These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Short Door-to-Needle Times in Acute Ischemic Stroke and Prospective Identification of Its Delaying Factors. Van Schaik SM; Scott S; de Lau LM; Van den Berg-Vos RM; Kruyt ND Cerebrovasc Dis Extra; 2015; 5(2):75-83. PubMed ID: 26265910 [TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Mazya MV; Lees KR; Markus R; Roine RO; Seet RC; Wahlgren N; Ahmed N; Ann Neurol; 2013 Aug; 74(2):266-74. PubMed ID: 23744571 [TBL] [Abstract][Full Text] [Related]
4. Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol. Tan BYQ; Ngiam NJH; Sunny S; Kong WY; Tam H; Sim TB; Leong BSH; Bhartendu C; Paliwal PR; Seet RCS; Chan BPL; Teoh HL; Sharma VK; Yeo LLL J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1539-1545. PubMed ID: 29422380 [TBL] [Abstract][Full Text] [Related]
5. Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator. Schrock JW; Lum M Am J Emerg Med; 2014 Nov; 32(11):1330-3. PubMed ID: 25195044 [TBL] [Abstract][Full Text] [Related]
6. Three easily-implementable changes reduce median door-to-needle time for intravenous thrombolysis by 23 minutes. Tran D; Zhu Z; Shafie M; Abcede H; Stradling D; Yu W BMC Neurol; 2019 Nov; 19(1):300. PubMed ID: 31771530 [TBL] [Abstract][Full Text] [Related]
7. Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan. Tanaka K; Matsumoto S; Yamada T; Nagano S; Takase KI; Hatano T; Yamasaki R; Kira JI J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104305. PubMed ID: 31405791 [TBL] [Abstract][Full Text] [Related]
8. Delayed Intravenous Thrombolysis in Patients with Minor Stroke. Yoo J; Sohn SI; Kim J; Ahn SH; Lee K; Baek JH; Kim K; Hong JH; Koo J; Kim YD; Kwak J; Nam HS; Heo JH Cerebrovasc Dis; 2018; 46(1-2):52-58. PubMed ID: 30092583 [TBL] [Abstract][Full Text] [Related]
10. Creation of an intensive care unit and organizational changes in an adult emergency department: Impact on acute stroke management. Puy L; Lamy C; Canaple S; Arnoux A; Laine N; Iacob E; Constans JM; Godefroy O Am J Emerg Med; 2017 May; 35(5):716-719. PubMed ID: 28096032 [TBL] [Abstract][Full Text] [Related]
11. Administration of tissue plasminogen activator without coagulation results in a Chinese population. Qin X; Zhao S; Yin L; Dou H; Chen J; Wang Y; Li M; Chen R; Fu J; Liu W; Liu X; Yang G; Wang R; Jia X; Bu S; Ma D; Wang B; Li S Neurol Sci; 2018 Mar; 39(3):481-487. PubMed ID: 29299775 [TBL] [Abstract][Full Text] [Related]
14. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513 [TBL] [Abstract][Full Text] [Related]
15. Multimodal strategy in the successful implementation of a stroke unit in a community hospital. Etgen T; Freudenberger T; Schwahn M; Rieder G; Sander D Acta Neurol Scand; 2011 Jun; 123(6):390-5. PubMed ID: 20704572 [TBL] [Abstract][Full Text] [Related]
16. Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR. Toni D; Ahmed N; Anzini A; Lorenzano S; Brozman M; Kaste M; Mikulik R; Putaala J; Wahlgren N; Neurology; 2012 Mar; 78(12):880-7. PubMed ID: 22402853 [TBL] [Abstract][Full Text] [Related]
17. Hospital variation in thrombolysis times among patients with acute ischemic stroke: the contributions of door-to-imaging time and imaging-to-needle time. Sauser K; Levine DA; Nickles AV; Reeves MJ JAMA Neurol; 2014 Sep; 71(9):1155-61. PubMed ID: 25023407 [TBL] [Abstract][Full Text] [Related]
18. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429 [TBL] [Abstract][Full Text] [Related]
19. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Ong CT; Wong YS; Wu CS; Su YH Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of early neurological deterioration after I.V - thrombolysis in acute ischaemic stroke patients - A hospital-based cohort study. Hansen CK; Christensen A; Havsteen I; Ovesen C; Christensen H Clin Neurol Neurosurg; 2018 Aug; 171():58-62. PubMed ID: 29843071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]